We will test the hypothesis that ongoing use of risperidone is superior to placebo with regard to behavioral symptoms in children and adolescents who have used risperidone for a year or longer.
ID
Bron
Verkorte titel
Aandoening
Risperidone, long-term efficacy and safety, risperidon, langetermijn effectiviteit
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
The primary outcome measure will be the D-total score of the Nisonger Child Behavior Rating Form-Typical IQ (NCBRF-TIQ).
Achtergrond van het onderzoek
The ORCA study is a multicenter, double blind, placebo-controlled discontinuation trial in which 120 children and adolescents (6 to 17;8 years, IQ> 70) who have been using risperidone for over a year, will at random either gradually discontinue to placebo or continue their use. Discontinuation will be done in an 8-week period, after which participants will use only placebo for 8 weeks. Measurements will take place at baseline, 8 weeks and 14 weeks after baseline and after 6 months (naturalistic).
The aim is to determine whether long-term use of risperidone after at least a year is still effective, to determine the effects of discontinuing on behavior and physical health and the feasibility of stopping this treatment.
Doel van het onderzoek
We will test the hypothesis that ongoing use of risperidone is superior to placebo with regard to behavioral symptoms in children and adolescents who have used risperidone for a year or longer.
Onderzoeksopzet
Baseline
8-week follow-up
14 week follow-up and immediate breaking of the blind
Naturalistic follow-up after 6 months
Onderzoeksproduct en/of interventie
The participating subjects will be randomized (ratio 1:1) to either continued use of risperidone or to placebo during sixteen weeks. After two weeks of accommodating to the study medication, withdrawal will be gradual over a period of six weeks, followed by eight weeks of complete placebo. There will be four visits, at the start of the study, at baseline and after eight and fourteen weeks after baseline. After six months there will be a follow up by telephone.
Publiek
M. Dinnissen
Postbus 30.001
Groningen 9700 RB
The Netherlands
Tel: 050 3610687
Mail: m.dinnissen@umcg.nl
Wetenschappelijk
M. Dinnissen
Postbus 30.001
Groningen 9700 RB
The Netherlands
Tel: 050 3610687
Mail: m.dinnissen@umcg.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
In order to be eligible to participate in this study, a subject must meet all of the following criteria:
- Be between the ages of six and seventeen years and eight months
- Current risperidone use ≥ one year.
- Current risperidone doses ≤ 5 mg/day.
- IQ > 70 (based on a previous IQ test or attending regular education).
- Parents (or the legal guardian) and children (≥ twelve years) have provided informed consent to participate in the study.
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
- Risperidone was discontinued for ≥ two months in the last year.
- Current psychosis.
- Pregnancy.
- Risperidone is primarily used for the treatment of psychosis or tics.
- Having parents who are planning to start other psychosocial and pharmacological therapies during the blinded period.
- Having parents who are unable to understand or comply with the protocol.
- Presence of any other significant disease or disorder which, in the opinion of the investigator, may either put the participants at risk because of participation in the study, or may influence the results of the study, or the participant’s ability to participate in the study.
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL5451 |
| NTR-old | NTR5595 |
| CCMO | NL52899.042.15 |
| OMON | NL-OMON44901 |